Expression and Clinical Significance of Serum Cyclooxygenase-2, Vascular Endothelial Growth Factor and Transforming Growth Factor-β1 in Chronic Myelogenous Leukemia
WANG Xiao-jun
RU Fu-yi
WU Shuang-you
ZHU Wei-min
TIAN Pei-jun
Abstract：Objective To observe changes of serum cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) levels in patients with chronic myelogenous leukemia (CML) and to discuss guidance significance of indexes.Methods A total of 50 patients with CML confirmed during January 2014 and Augest 2015 (leukemia group) were treated with Imatinib Mesylate for 3 months, and other 40 healthy people taking medical examination were selected as control group.Changes of serum COX-2, VEGF and TGF-β1 levels were compared in two groups, and changes of the levels before and after treatment in leukemia group were observed.Results Compared with those in control group, before and after treatment, serum COX-2 and VEGF levels were significantly increased, while TGF-β1 level was significantly decreases in leukemia group (P<0.01);compared with those before treatment, in leukemia group, serum COX-2 and VEGF levels were significantly decreased;while TGF-β1 level was significantly increased after treatment (P<0.01).In leukemia group, before treatment serum VEGF and COX-2 levels were significantly increased, while TGF-β1 levels were significantly decreased in acute transformation phase and accelerated-phase compared with those in chronic-phase (P<0.01);after treatment, COX-2, VEGF and TGF-β1 levels of complete remission (CR) patients returned to normal, and the differences in the levels compared with those in non-remission (NR) patients were statistically significant (P<0.01).Serum COX-2 and VEGF levels were negatively correlated with TGF-β1 level in leukemia group (R=-0.632, P<0.01;R=-0.315, P=0.026).Conclusion COX-2, VEGF and TGF-β1 levels are closely related to conditions of patients with CML, and therefore they can be used as important revidence of disease for evaluating CML condition.
Keywords：Granulocytic leukemiachronicCyclooxygenase-2Vascular endothelial growth factorTransforming growth factor beta 1
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 99-102 )